Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Aldurazyme Patient Registry Will Evaluate AEs, Antibody Formation

Executive Summary

BioMarin/Genzyme will develop an Aldurazyme patient registry to evaluate the long-term safety and activity of the product

You may also be interested in...



TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA

Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006

TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA

Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006

Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street

Millennium's multiple myeloma agent Velcade is leading the parade of oncologic therapies attracting renewed enthusiasms from investors

Related Content

UsernamePublicRestriction

Register

PS041735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel